A randomized, double-blind, placebo-controlled clinical study of 300 patients showed that Jinhua Qinggan granules significantly reduced the levels of leukocytes, ferritin, and CRP, shortened the median recovery time of symptoms associated with COVID-19 (including cough, sputum, sore throat, dyspnea, headache, nasal congestion, fatigue and myalgia), and show a low incidence of adverse events (3 mild to moderate adverse events) that were well tolerated by patients (Shah et al., 2022). This evidence concerns the gene CRP and Myalgia.